Harel Insurance Investments & Financial Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-80	Closed	-$6K	–	429
2016 Q3	$6K	Sell	80 -30	-27%	-$1.92K	﹤0.01%	414
2016 Q2	$5K	Hold	110	–	–	﹤0.01%	625
2016 Q1	$7K	Sell	110 -154	-58%	-$10.1K	﹤0.01%	394
2015 Q4	$30K	Buy	+264	New	+$26.4K	﹤0.01%	228

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harel Insurance Investments & Financial Services's RARE Position: Q4 2016 in Review

Harel Insurance Investments & Financial Services sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 80 shares — an estimated $6K sold.

Harel Insurance Investments & Financial Services first reported a position in RARE in Q4 2015 and held it in 4 quarters. The position peaked at $30K in Q4 2015. 175 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

Harel Insurance Investments & Financial Services reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 80 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $6K.
Harel Insurance Investments & Financial Services first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 4 quarters.
Harel Insurance Investments & Financial Services's Ultragenyx Pharmaceutical position peaked at $30K in Q4 2015.
175 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2016, filed 6 Feb 2017.